CSL is a leading global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat hemophilia and immune deficiencies, as well as vaccines to prevent influenza. It comprises CSL Behring, CSL Seqirus, and CSL Vifor, providing diverse offerings to ensure patients and people everywhere get the treatments they need.

Marsden Eye Specialists is involved in eye surgery and the treatment of various eye conditions such as cataracts, glaucoma, and retinal diseases. It also offers laser vision correction services.

Marsden Eye Specialists

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

ADMA Biologics, Inc.

Switzerland Innovation Park Basel Area provides ready-made and customizable workspaces for various teams, focusing on innovation in healthcare, life sciences, and technology.

Switzerland Innovation Park Basel Area

CSL Plasma

CSL Vifor

CSL is a leading global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency, dialysis and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies.

Today, CSL – including our businesses, CSL Behring, CSL Seqirus, CSL Plasma and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs 32,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest.

See our community guidelines: https://bit.ly/3Bs17Ra

CEO and Managing Director Paul McKenzie speaks to the outlook for CSL.  A recording of the half year earnings webcast can be found at our investor center:  https://bit.ly/48vgIhb #CSL 

CSL's CEO and Managing Director Paul McKenzie summarizes our financial performance for the first half of FY2024.  More: https://bit.ly/42EUzvj 

We have just released our half year results for financial year 2024. Check out a snapshot below, or head to our investor center for more information. https://bit.ly/4bAsSaX 

CSL’s Head of Research & Development, Dr. Bill Mezzanotte, weighs in on how the AEGIS-II program has left a lasting impact on our organization. Read more: https://bit.ly/49zh3Aj 

Today, we announced top-line results from the Phase 3 AEGIS-II trial. Read more: https://bit.ly/3I0ZVaA #CSL

Today, on the International Day of Women and Girls in Science, we uplift and celebrate the phenomenal women and girls who innovate, discover and inspire in the field of science!  Your pursuits push boundaries and forge a future in which every dream is possible.

Explore career opportunities at CSL: https://bit.ly/42QWopj

#InternationalDayOfWomenAndGirlsInScience #PromisingFutures #CSL


Metric
Company Name	CSL	Marsden Eye Specialists	ADMA Biologics, Inc.	Switzerland Innovation Park Basel Area
Symbol			ADMA
MSH ID	COM:CSL	AU:COM:MARSDENEYE	COM:ADMABIOLOGICS	COM:SIP-BASELAREA
Market	PRIVATE	PRIVATE	STOCKS	PRIVATE
Sector	Healthcare & Health Services	Healthcare & Health Services	Healthcare	Commercial & Professional Services
Industry	Biotechnology and Pharmaceuticals	Healthcare	Biotechnology	Real Estate
Country	AU	AU	US	CH
Stage
Employee Count	20.94K		624
Website	csl.com	marsdeneye.com.au	admabiologics.com	sip-baselarea.com
LinkedIn	csl			switzerland-innovation-park-basel-area
Founders

Metric
Market Cap			2.78B
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue			258.21M
Revenue (LTM)
Revenue (NTM)
Gross Profit			88.22M
EBITDA			29.96M
Operating Income			21.63M
Net Income			-28.24M
EPS			-0.13
Diluted EPS			-0.13
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin			0.46
Operating Profit Margin			0.25
EBITDA Margin			0.12
Net Profit Margin			0.11
Return on Equity			0.22
Return on Assets			0.09
Return on Capital Employed			0.25

COM:CSL

CSL

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio			-27.46
P/B Ratio			7.71
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio			14.73
EV Multiple			57.98

Metric
Days Sales Outstanding			48.79
Days Payables Outstanding			24.41
Days Inventory Outstanding			377.54
Operating Cycle			441.50
Cash Conversion Cycle			405.00
Asset Turnover			0.88

Metric
Operating Cash Flow			8.80M
Free Cash Flow			3.82M
Cash Flow to Debt			0.55
Operating Cash Flow/Sales			0.22
Free Cash Flow Yield			-0.02

Metric
Cash & Equivalents			51.35M
Accounts Receivable			-11.92M
Inventory			172.91M
Goodwill			3.53M
Debt to Capitalization			0.49
Debt to Assets			0.44
Current Ratio			6.54
Quick Ratio			2.80

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue			0.02
R&D to Revenue			0.02
SG&A to Revenue